Publications by authors named "Lidia Rombeallo"
Background: DLBS3233, recognized as an agent enhancing insulin sensitivity, has exhibited promise as a therapeutic option for addressing type 2 diabetes mellitus (T2DM). This study aimed to evaluate the effectiveness and safety of DLBS3233, a natural compound, in individuals newly diagnosed with T2DM.
Methods: A 12-week double-blind, randomized, placebo-controlled clinical trial was conducted with 104 eligible participants.